US Biotech Biz Says Rival's Gene Editing Patent Is Invalid
A U.S. biotech company and two manufacturers have denied they infringed a South Korean rival's gene-editing patent, urging a London court to declare the patent invalid....To view the full article, register now.
Already a subscriber? Click here to view full article